---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-130779"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:08:38.671639+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics adopts limited-duration poison pill after recent stock accumulations

## Summary
- Board adopted Rights Agreement effective May 2, 2024, responding to recent accumulations of common stock.
- Each outstanding common share receives one right; triggers at 10% beneficial ownership without Board approval.
- Upon trigger, rights holders (except acquirer) can buy shares at 50% discount; rights expire May 2, 2025.
- Record date for dividend of rights is May 20, 2024; exercise price $1.50 per right.

## SEC filing metadata
- accession: 0001193125-24-130779
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/0001193125-24-130779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/d835891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-130779
- JSON: https://secwatch.observer/filing/0001193125-24-130779.json
- Plain text: https://secwatch.observer/filing/0001193125-24-130779.txt

## Key facts
- Governance Changes
  Galera Therapeutics, Inc.: Board approved a Certificate of Designation creating Series A Junior Participating Preferred Stock in connection with the adoption of a stockholder rights agreement (effective 2024-05-03).
  - Change: charter amendment
  - Effective: 2024-05-03
  source text: In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 200,000 shares of a series of the Company’s preferred stock, par value $0.001 per share, designated as Series A Junior Participating Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524130779/0001193125-24-130779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.